In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry

Pretargeted imaging has emerged as an effective multistep strategy aiming to improve imaging contrast and reduce patient radiation exposure through decoupling of the radioactivity from the targeting vector. The inverse electron-demand Diels–Alder (IEDDA) reaction between a trans-cyclooctene (TCO)-co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioconjugate chemistry 2021-01, Vol.32 (1), p.121-132
Hauptverfasser: Ferreira, Vera F. C, Oliveira, Bruno L, D’Onofrio, Alice, Farinha, Carlos M, Gano, Lurdes, Paulo, António, Bernardes, Gonçalo J. L, Mendes, Filipa
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 132
container_issue 1
container_start_page 121
container_title Bioconjugate chemistry
container_volume 32
creator Ferreira, Vera F. C
Oliveira, Bruno L
D’Onofrio, Alice
Farinha, Carlos M
Gano, Lurdes
Paulo, António
Bernardes, Gonçalo J. L
Mendes, Filipa
description Pretargeted imaging has emerged as an effective multistep strategy aiming to improve imaging contrast and reduce patient radiation exposure through decoupling of the radioactivity from the targeting vector. The inverse electron-demand Diels–Alder (IEDDA) reaction between a trans-cyclooctene (TCO)-conjugated antibody and a labeled tetrazine holds great promise for pretargeted imaging applications due to its bioorthogonality, rapid kinetics under mild conditions, and formation of stable products. Herein, we describe the use of functionalized carbonylacrylic reagents for site-specific incorporation of TCO onto a human epidermal growth factor receptor 2 (HER2) antibody (THIOMAB) containing an engineered unpaired cysteine residue, generating homogeneous conjugates. Precise labeling of THIOMAB–TCO with a fluorescent or radiolabeled tetrazine revealed the potential of the TCO-functionalized antibody for imaging the HER2 after pretargeting in a cellular context in a HER2 positive breast cancer cell line. Control studies with MDA–MD-231 cells, which do not express HER2, further confirmed the target specificity of the modified antibody. THIOMAB–TCO was also evaluated in vivo after pretargeting and subsequent administration of an 111In-labeled tetrazine. Biodistribution studies in breast cancer tumor-bearing mice showed a significant activity accumulation on HER2+ tumors, which was 2.6-fold higher than in HER2– tumors. Additionally, biodistribution studies with THIOMAB without the TCO handle also resulted in a decreased uptake of 111In–DOTA–Tz on HER2+ tumors. Altogether, these results clearly indicate the occurrence of the click reaction at the tumor site, i.e., pretargeting of SK-BR-3 HER2-expressing cells with THIOMAB–TCO and reaction through the TCO moiety present in the antibody. The combined advantages of site-selectivity and stability of TCO tagged-antibodies could allow application of biorthogonal chemistry strategies for pretargeting imaging with minimal side-reactions and background.
doi_str_mv 10.1021/acs.bioconjchem.0c00551
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2483640822</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2483640822</sourcerecordid><originalsourceid>FETCH-LOGICAL-a460t-4512981a2ddd07700d9b0c70b209a2ae083c465927de21a38d924d3b16e1ba9d3</originalsourceid><addsrcrecordid>eNqFkE1vEzEQhi1ERUvLXwAjzpuOP_brmG4LjVQEEoWr5bUnicNmndpOUMSfx1FCxY2TfXjmnXceQt4xmDDg7FqbOOmdN35cmSWuJ2AAypK9IBes5FDIhvGX-Q9SFKwBfk5ex7gCgJY1_BU5F4K3ZV1WF-T3bKQ_3M7TrwGTDgtMblzQGx3RUj_Sbh8TuhGLbzigSW6HdDom13u7p5-9dXNndHIZ_OXSks7ubm-n9MZ5H9LSL_yoB3qvRztgpHMfaDc485N2ubCLKeyvyNlcDxHfnN5L8v3j3WN3Xzx8-TTrpg-FlhWkQpaMtw3T3FoLdQ1g2x5MDT2HVnON0Agjq7LltUXOtGhsy6UVPauQ9bq14pJ8OOZugn_aYkxq5bchl4uKy0ZUEhrOM1UfKRN8jAHnahPcWoe9YqAO0lWWrv6Rrk7S8-TbU_62X6N9nvtrOQPvj0AwWm9UwF2-X8ecmm9TsubsECKOzGHLc7__rf4DJOmegw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2483640822</pqid></control><display><type>article</type><title>In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry</title><source>ACS Publications</source><creator>Ferreira, Vera F. C ; Oliveira, Bruno L ; D’Onofrio, Alice ; Farinha, Carlos M ; Gano, Lurdes ; Paulo, António ; Bernardes, Gonçalo J. L ; Mendes, Filipa</creator><creatorcontrib>Ferreira, Vera F. C ; Oliveira, Bruno L ; D’Onofrio, Alice ; Farinha, Carlos M ; Gano, Lurdes ; Paulo, António ; Bernardes, Gonçalo J. L ; Mendes, Filipa</creatorcontrib><description>Pretargeted imaging has emerged as an effective multistep strategy aiming to improve imaging contrast and reduce patient radiation exposure through decoupling of the radioactivity from the targeting vector. The inverse electron-demand Diels–Alder (IEDDA) reaction between a trans-cyclooctene (TCO)-conjugated antibody and a labeled tetrazine holds great promise for pretargeted imaging applications due to its bioorthogonality, rapid kinetics under mild conditions, and formation of stable products. Herein, we describe the use of functionalized carbonylacrylic reagents for site-specific incorporation of TCO onto a human epidermal growth factor receptor 2 (HER2) antibody (THIOMAB) containing an engineered unpaired cysteine residue, generating homogeneous conjugates. Precise labeling of THIOMAB–TCO with a fluorescent or radiolabeled tetrazine revealed the potential of the TCO-functionalized antibody for imaging the HER2 after pretargeting in a cellular context in a HER2 positive breast cancer cell line. Control studies with MDA–MD-231 cells, which do not express HER2, further confirmed the target specificity of the modified antibody. THIOMAB–TCO was also evaluated in vivo after pretargeting and subsequent administration of an 111In-labeled tetrazine. Biodistribution studies in breast cancer tumor-bearing mice showed a significant activity accumulation on HER2+ tumors, which was 2.6-fold higher than in HER2– tumors. Additionally, biodistribution studies with THIOMAB without the TCO handle also resulted in a decreased uptake of 111In–DOTA–Tz on HER2+ tumors. Altogether, these results clearly indicate the occurrence of the click reaction at the tumor site, i.e., pretargeting of SK-BR-3 HER2-expressing cells with THIOMAB–TCO and reaction through the TCO moiety present in the antibody. The combined advantages of site-selectivity and stability of TCO tagged-antibodies could allow application of biorthogonal chemistry strategies for pretargeting imaging with minimal side-reactions and background.</description><identifier>ISSN: 1043-1802</identifier><identifier>EISSN: 1520-4812</identifier><identifier>DOI: 10.1021/acs.bioconjchem.0c00551</identifier><identifier>PMID: 33295756</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Antibodies ; Breast cancer ; Carbonyls ; Chemical reactions ; Chemical synthesis ; Cysteine ; Decoupling ; Epidermal growth factor ; ErbB-2 protein ; Fluorescence ; Growth factors ; Handles ; Imaging ; In vivo methods and tests ; Radiation ; Radiation effects ; Radioactivity ; Reagents ; Selectivity ; Tumors</subject><ispartof>Bioconjugate chemistry, 2021-01, Vol.32 (1), p.121-132</ispartof><rights>2020 American Chemical Society</rights><rights>Copyright American Chemical Society Jan 20, 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a460t-4512981a2ddd07700d9b0c70b209a2ae083c465927de21a38d924d3b16e1ba9d3</citedby><cites>FETCH-LOGICAL-a460t-4512981a2ddd07700d9b0c70b209a2ae083c465927de21a38d924d3b16e1ba9d3</cites><orcidid>0000-0001-6594-8917 ; 0000-0001-6740-8607 ; 0000-0003-0646-1687 ; 0000-0002-5467-1710 ; 0000-0002-7687-4746</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.0c00551$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.bioconjchem.0c00551$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33295756$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ferreira, Vera F. C</creatorcontrib><creatorcontrib>Oliveira, Bruno L</creatorcontrib><creatorcontrib>D’Onofrio, Alice</creatorcontrib><creatorcontrib>Farinha, Carlos M</creatorcontrib><creatorcontrib>Gano, Lurdes</creatorcontrib><creatorcontrib>Paulo, António</creatorcontrib><creatorcontrib>Bernardes, Gonçalo J. L</creatorcontrib><creatorcontrib>Mendes, Filipa</creatorcontrib><title>In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry</title><title>Bioconjugate chemistry</title><addtitle>Bioconjugate Chem</addtitle><description>Pretargeted imaging has emerged as an effective multistep strategy aiming to improve imaging contrast and reduce patient radiation exposure through decoupling of the radioactivity from the targeting vector. The inverse electron-demand Diels–Alder (IEDDA) reaction between a trans-cyclooctene (TCO)-conjugated antibody and a labeled tetrazine holds great promise for pretargeted imaging applications due to its bioorthogonality, rapid kinetics under mild conditions, and formation of stable products. Herein, we describe the use of functionalized carbonylacrylic reagents for site-specific incorporation of TCO onto a human epidermal growth factor receptor 2 (HER2) antibody (THIOMAB) containing an engineered unpaired cysteine residue, generating homogeneous conjugates. Precise labeling of THIOMAB–TCO with a fluorescent or radiolabeled tetrazine revealed the potential of the TCO-functionalized antibody for imaging the HER2 after pretargeting in a cellular context in a HER2 positive breast cancer cell line. Control studies with MDA–MD-231 cells, which do not express HER2, further confirmed the target specificity of the modified antibody. THIOMAB–TCO was also evaluated in vivo after pretargeting and subsequent administration of an 111In-labeled tetrazine. Biodistribution studies in breast cancer tumor-bearing mice showed a significant activity accumulation on HER2+ tumors, which was 2.6-fold higher than in HER2– tumors. Additionally, biodistribution studies with THIOMAB without the TCO handle also resulted in a decreased uptake of 111In–DOTA–Tz on HER2+ tumors. Altogether, these results clearly indicate the occurrence of the click reaction at the tumor site, i.e., pretargeting of SK-BR-3 HER2-expressing cells with THIOMAB–TCO and reaction through the TCO moiety present in the antibody. The combined advantages of site-selectivity and stability of TCO tagged-antibodies could allow application of biorthogonal chemistry strategies for pretargeting imaging with minimal side-reactions and background.</description><subject>Antibodies</subject><subject>Breast cancer</subject><subject>Carbonyls</subject><subject>Chemical reactions</subject><subject>Chemical synthesis</subject><subject>Cysteine</subject><subject>Decoupling</subject><subject>Epidermal growth factor</subject><subject>ErbB-2 protein</subject><subject>Fluorescence</subject><subject>Growth factors</subject><subject>Handles</subject><subject>Imaging</subject><subject>In vivo methods and tests</subject><subject>Radiation</subject><subject>Radiation effects</subject><subject>Radioactivity</subject><subject>Reagents</subject><subject>Selectivity</subject><subject>Tumors</subject><issn>1043-1802</issn><issn>1520-4812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkE1vEzEQhi1ERUvLXwAjzpuOP_brmG4LjVQEEoWr5bUnicNmndpOUMSfx1FCxY2TfXjmnXceQt4xmDDg7FqbOOmdN35cmSWuJ2AAypK9IBes5FDIhvGX-Q9SFKwBfk5ex7gCgJY1_BU5F4K3ZV1WF-T3bKQ_3M7TrwGTDgtMblzQGx3RUj_Sbh8TuhGLbzigSW6HdDom13u7p5-9dXNndHIZ_OXSks7ubm-n9MZ5H9LSL_yoB3qvRztgpHMfaDc485N2ubCLKeyvyNlcDxHfnN5L8v3j3WN3Xzx8-TTrpg-FlhWkQpaMtw3T3FoLdQ1g2x5MDT2HVnON0Agjq7LltUXOtGhsy6UVPauQ9bq14pJ8OOZugn_aYkxq5bchl4uKy0ZUEhrOM1UfKRN8jAHnahPcWoe9YqAO0lWWrv6Rrk7S8-TbU_62X6N9nvtrOQPvj0AwWm9UwF2-X8ecmm9TsubsECKOzGHLc7__rf4DJOmegw</recordid><startdate>20210120</startdate><enddate>20210120</enddate><creator>Ferreira, Vera F. C</creator><creator>Oliveira, Bruno L</creator><creator>D’Onofrio, Alice</creator><creator>Farinha, Carlos M</creator><creator>Gano, Lurdes</creator><creator>Paulo, António</creator><creator>Bernardes, Gonçalo J. L</creator><creator>Mendes, Filipa</creator><general>American Chemical Society</general><general>ACS Publications</general><scope>RCLKO</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0001-6594-8917</orcidid><orcidid>https://orcid.org/0000-0001-6740-8607</orcidid><orcidid>https://orcid.org/0000-0003-0646-1687</orcidid><orcidid>https://orcid.org/0000-0002-5467-1710</orcidid><orcidid>https://orcid.org/0000-0002-7687-4746</orcidid></search><sort><creationdate>20210120</creationdate><title>In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry</title><author>Ferreira, Vera F. C ; Oliveira, Bruno L ; D’Onofrio, Alice ; Farinha, Carlos M ; Gano, Lurdes ; Paulo, António ; Bernardes, Gonçalo J. L ; Mendes, Filipa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a460t-4512981a2ddd07700d9b0c70b209a2ae083c465927de21a38d924d3b16e1ba9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Breast cancer</topic><topic>Carbonyls</topic><topic>Chemical reactions</topic><topic>Chemical synthesis</topic><topic>Cysteine</topic><topic>Decoupling</topic><topic>Epidermal growth factor</topic><topic>ErbB-2 protein</topic><topic>Fluorescence</topic><topic>Growth factors</topic><topic>Handles</topic><topic>Imaging</topic><topic>In vivo methods and tests</topic><topic>Radiation</topic><topic>Radiation effects</topic><topic>Radioactivity</topic><topic>Reagents</topic><topic>Selectivity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ferreira, Vera F. C</creatorcontrib><creatorcontrib>Oliveira, Bruno L</creatorcontrib><creatorcontrib>D’Onofrio, Alice</creatorcontrib><creatorcontrib>Farinha, Carlos M</creatorcontrib><creatorcontrib>Gano, Lurdes</creatorcontrib><creatorcontrib>Paulo, António</creatorcontrib><creatorcontrib>Bernardes, Gonçalo J. L</creatorcontrib><creatorcontrib>Mendes, Filipa</creatorcontrib><collection>RCAAP open access repository</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Bioconjugate chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ferreira, Vera F. C</au><au>Oliveira, Bruno L</au><au>D’Onofrio, Alice</au><au>Farinha, Carlos M</au><au>Gano, Lurdes</au><au>Paulo, António</au><au>Bernardes, Gonçalo J. L</au><au>Mendes, Filipa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry</atitle><jtitle>Bioconjugate chemistry</jtitle><addtitle>Bioconjugate Chem</addtitle><date>2021-01-20</date><risdate>2021</risdate><volume>32</volume><issue>1</issue><spage>121</spage><epage>132</epage><pages>121-132</pages><issn>1043-1802</issn><eissn>1520-4812</eissn><abstract>Pretargeted imaging has emerged as an effective multistep strategy aiming to improve imaging contrast and reduce patient radiation exposure through decoupling of the radioactivity from the targeting vector. The inverse electron-demand Diels–Alder (IEDDA) reaction between a trans-cyclooctene (TCO)-conjugated antibody and a labeled tetrazine holds great promise for pretargeted imaging applications due to its bioorthogonality, rapid kinetics under mild conditions, and formation of stable products. Herein, we describe the use of functionalized carbonylacrylic reagents for site-specific incorporation of TCO onto a human epidermal growth factor receptor 2 (HER2) antibody (THIOMAB) containing an engineered unpaired cysteine residue, generating homogeneous conjugates. Precise labeling of THIOMAB–TCO with a fluorescent or radiolabeled tetrazine revealed the potential of the TCO-functionalized antibody for imaging the HER2 after pretargeting in a cellular context in a HER2 positive breast cancer cell line. Control studies with MDA–MD-231 cells, which do not express HER2, further confirmed the target specificity of the modified antibody. THIOMAB–TCO was also evaluated in vivo after pretargeting and subsequent administration of an 111In-labeled tetrazine. Biodistribution studies in breast cancer tumor-bearing mice showed a significant activity accumulation on HER2+ tumors, which was 2.6-fold higher than in HER2– tumors. Additionally, biodistribution studies with THIOMAB without the TCO handle also resulted in a decreased uptake of 111In–DOTA–Tz on HER2+ tumors. Altogether, these results clearly indicate the occurrence of the click reaction at the tumor site, i.e., pretargeting of SK-BR-3 HER2-expressing cells with THIOMAB–TCO and reaction through the TCO moiety present in the antibody. The combined advantages of site-selectivity and stability of TCO tagged-antibodies could allow application of biorthogonal chemistry strategies for pretargeting imaging with minimal side-reactions and background.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>33295756</pmid><doi>10.1021/acs.bioconjchem.0c00551</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-6594-8917</orcidid><orcidid>https://orcid.org/0000-0001-6740-8607</orcidid><orcidid>https://orcid.org/0000-0003-0646-1687</orcidid><orcidid>https://orcid.org/0000-0002-5467-1710</orcidid><orcidid>https://orcid.org/0000-0002-7687-4746</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1043-1802
ispartof Bioconjugate chemistry, 2021-01, Vol.32 (1), p.121-132
issn 1043-1802
1520-4812
language eng
recordid cdi_proquest_journals_2483640822
source ACS Publications
subjects Antibodies
Breast cancer
Carbonyls
Chemical reactions
Chemical synthesis
Cysteine
Decoupling
Epidermal growth factor
ErbB-2 protein
Fluorescence
Growth factors
Handles
Imaging
In vivo methods and tests
Radiation
Radiation effects
Radioactivity
Reagents
Selectivity
Tumors
title In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T10%3A25%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Vivo%20Pretargeting%20Based%20on%20Cysteine-Selective%20Antibody%20Modification%20with%20IEDDA%20Bioorthogonal%20Handles%20for%20Click%20Chemistry&rft.jtitle=Bioconjugate%20chemistry&rft.au=Ferreira,%20Vera%20F.%20C&rft.date=2021-01-20&rft.volume=32&rft.issue=1&rft.spage=121&rft.epage=132&rft.pages=121-132&rft.issn=1043-1802&rft.eissn=1520-4812&rft_id=info:doi/10.1021/acs.bioconjchem.0c00551&rft_dat=%3Cproquest_cross%3E2483640822%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2483640822&rft_id=info:pmid/33295756&rfr_iscdi=true